GLP-1 therapy produces substantial, sustained weight loss
GLP-1 therapy
In the STEP-1 trial, once-weekly semaglutide 2.4 mg produced a mean weight reduction of roughly 15% over 68 weeks alongside lifestyle intervention — a magnitude not previously seen with medical therapy.
Why it matters
It establishes GLP-1 medication as a genuinely effective tool for weight loss — the foundation both Vitelize tracks are built around.
Our reading
Effective, yes — but weight lost is not the whole story. What that weight is made of is the question the rest of this page addresses.
Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989–1002.
Peer-reviewed
Dual GIP/GLP-1 agonism deepens the effect
GLP-1 therapy
In SURMOUNT-1, tirzepatide — a dual GIP and GLP-1 receptor agonist — produced mean weight reductions of up to roughly 21% at the highest dose over 72 weeks, with accompanying improvements in cardiometabolic measures.
Why it matters
It supports the clinical rationale for tirzepatide as the stronger option within our menu, when a clinician judges it appropriate.
Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
Peer-reviewed
A meaningful share of weight lost can be lean mass
Lean mass
Body-composition sub-analyses of GLP-1 and dual-agonist trials, using DEXA, have reported that a substantial portion of total weight lost is fat-free (lean) mass rather than fat alone.
Important nuance
Some loss of lean mass is expected with any significant weight loss. The clinical question is how much, and whether it can be reduced — not whether it occurs at all.
Our reading
This is the single finding that most shapes our model: medication alone leaves lean-mass protection to chance. We choose not to.
Body-composition sub-studies reported within the STEP and SURMOUNT trial programs (NEJM, 2021–2022). Figures describe published research, not Vitelize outcomes.
Peer-reviewed
Resistance training during weight loss helps preserve lean mass
Resistance training
Across systematic reviews and meta-analyses of caloric-restriction studies, adding resistance training is consistently associated with greater retention of lean mass compared with diet or aerobic exercise alone.
Why it matters
It is the mechanistic basis for pairing supervised resistance training with GLP-1 therapy in Track One.
Honest limits
Most of this literature predates GLP-1 medications. Direct trials combining resistance training with GLP-1 therapy are still emerging.
Synthesized from systematic reviews of resistance training under caloric restriction (e.g., reviews published in Obesity Reviews and Nutrients). Specific effect sizes vary by population.
Peer-reviewed Open question
Higher protein intake supports lean-mass retention
Protein & nutrition
Professional-society guidance recommends elevated protein intake during weight loss to help protect muscle. Position papers commonly cite ranges above the standard RDA — often in the region of 1.2–1.6 g/kg/day for active adults and those losing weight.
Why it matters
It is why every Vitelize nutrition plan targets this protein range and includes supplemental protein.
Jäger R et al. International Society of Sports Nutrition Position Stand: Protein and Exercise. J Int Soc Sports Nutr 2017;14:20. Bauer J et al. (PROT-AGE Study Group). J Am Med Dir Assoc 2013;14:542–559.
Clinical guidance
Scale weight hides body composition
Body composition
Total body weight cannot distinguish fat loss from muscle loss. Methods such as DEXA and bioelectrical impedance analysis (BIA) estimate fat mass and lean mass separately, revealing changes the scale cannot.
Our reading
If lean mass is what you are trying to protect, you have to measure it. That is why body-composition tracking — not just weigh-ins — is built into the program.
Honest limits
BIA is a practical estimate, not a lab-grade reference method. We use it to track trends over time, not to certify an exact number.
General principle from body-composition measurement literature; DEXA and BIA are established, widely used methods with known trade-offs.
Vitelize interpretation
Stopping the medication often brings weight back
Weight maintenance
In the STEP-4 withdrawal trial, participants who stopped semaglutide regained a large share of the weight they had lost over the following year. SURMOUNT-4 reported substantial regain after tirzepatide withdrawal as well.
Why it matters
It reframes the goal from a temporary drop on the scale to durable change — the reason our model includes a clinician-guided taper and a maintenance plan.
Our reading
Regain is not a personal failure; it is a predictable physiological response. Building strength and habits during treatment is how we try to change the trajectory after it.
Rubino D et al. Effect of Continued vs Withdrawn Semaglutide on Weight Maintenance (STEP 4). JAMA 2021;325:1414–1425. Aronne LJ et al. Continued Treatment with Tirzepatide (SURMOUNT 4). JAMA 2024;331:38–48.
Peer-reviewed
Muscle is a metabolic organ, not just movement
Metabolic health
Skeletal muscle is a primary site of glucose disposal and a driver of resting energy expenditure. Research in muscle and metabolic health links greater muscle quality and function to better long-term metabolic outcomes.
Why it matters
Protecting muscle is not only about strength or appearance — it is about protecting the metabolic capacity that helps keep weight off.
Established physiology of skeletal muscle in glucose metabolism and energy expenditure; an active area of research led by investigators including Vitelize scientific advisor Prof. Stuart Gray (University of Glasgow).
Clinical guidance
Do combined programs beat medication alone, long term?
Metabolic health
The intuitive case for combining GLP-1 therapy with structured training, nutrition and monitoring is strong. Rigorous, long-horizon trials directly comparing that combination against medication alone are still limited.
Where we stand
We build our model on the best available mechanistic and trial evidence while being candid that the definitive head-to-head, long-term comparison is an open question the field is still answering.
Reflects the current state of the published literature as we read it; not a claim of proven superiority.
Open question Vitelize interpretation
References are provided for transparency and education. This page summarizes published research and professional guidance; it is not medical advice and does not describe outcomes achieved by Vitelize patients. Individual results vary and depend on clinical evaluation. Where a trial figure is cited, it describes that study’s population, not a Vitelize result.